After treatment, compared with the control group, the treatment group showed significant advantages in increasing the levels of CD3+ and CD4+, and reducing the level of CD8+ (CD3+: AMD = 3.55%, 95% CI: 1.88–5.22, P < 0.001; CD4+: AMD = 5.05%, 95% CI: 2.58–7.52, P < 0.001; CD8+: AMD = −8.55%, 95% CI: −9.72 to −7.38, P < 0.001) (see Table 8). The gene discussed is CD4; the disease is age-related macular degeneration.